A recent federal complaint filed by a former executive claims that Illinois cannabis regulators detected serious discrepancies at Curaleaf’s Litchfield cultivation facility, raising suspicions of “systemic diversion” across the multistate operator’s supply chain.
Ex-Compliance Director Places Red Flag on Inventory Gaps
The lawsuit, lodged July 29 in U.S. District Court for the Northern District of Illinois by ex-regional compliance director Matthew Kalmick, asserts that state regulators repeatedly observed significant volumes of cannabis inventory unaccounted for at the Litchfield site. State-level oversight, according to the complaint, raised alarms about potential systemic theft.
Beyond missing product, the complaint details additional health, safety, and compliance issues. Among them: unlicensed pesticide use, improperly stored chemicals, obstructed emergency exits, and inadequate use of personal protective equipment (PPE). These concerns, the suit claims, were raised by Bresha Brewer, at the time the Illinois Department of Agriculture’s cannabis bureau chief.
Escalation, Ignored Warnings, and Termination
Kalmick says he escalated the concerns internally, reporting them to senior leadership, including a vice president, only to be met with silence. The suit alleges that Curaleaf failed to act, even after Illinois regulators imposed penalties in January 2024 for pesticide violations.
Tensions peaked following a February 2024 inspection. According to the complaint, regulators halted all product shipments from the Litchfield facility, citing serious issues: missing units, mislabeled inventory, and unlabeled or unpaired items. The suit further contends that Curaleaf’s leadership retaliated against Kalmick by blocking his promotion and ultimately terminating his employment in May 2024 under a purported legal pretext.
Kalmick’s remaining claims include violations of state and federal whistleblower protections and employment statutes. He is asking for unspecified damages and a jury trial.
Why These Allegations Are Uncommon in Illinois
Cannabis diversion, where product from the regulated system leaks to the illicit market, is a common allegation in many state markets. But Illinois is a notable exception. The state limits both the number of cultivation licenses and the allowable canopy size for flowering plants, which constrains oversupply and, theoretically, reduces the incentive for diversion.
Despite those controls, the complaint notes that Illinois cannabis prices declined modestly in 2024, a trend the plaintiff connects to regulatory concerns flagged at Curaleaf. The state currently authorizes up to 21 large cultivation centers, each capped at 210,000 square feet of flowering space.
Big multistate players such as Green Thumb Industries and Cresco Labs are among those holding Illinois cultivation permits.
Responses, Confidentiality, and Unanswered Questions
Curaleaf declined to comment when MJ Biz Daily reached via written request. The company has asked the court for a three-week extension to respond to the complaint
Illinois state law keeps investigations and inspections of cannabis licensees confidential, limiting public insight into the scope and outcome of regulatory findings. A DOA spokesperson, Lori Harlan, confirmed this confidentiality mandate but declined further comment.
The case is drawing attention because it comes from a senior insider and raises diversion allegations in a tightly regulated state, territory where such claims are rarely made public.
Stay in the loop with all things Illinois Cannabis by joining the Couch Lock’d Newsletter here!
Follow our NEW Instagram here!
Become a Couch Lock’d Member.
Want to meet more people in the community and see what everyone’s smoking on? Join our Telegram channel here.
Find our latest reviews here.
Hosting an event & need a consumption bar? Hit us up here.
Save money with our affiliate links here.
Get your Illinois Medical Card for $75 now with our link here or code “CouchLockd”!